A global biotech platform that envisions an end to mental illnesses, today announced an investment in two separate joint ventures (JV) with DemeRx, a clinical stage pharmaceutical company focused on developing ibogaine and noribogaine for the treatment of opioid use disorder (OUD).
ATAI Life Sciences Announces Joint Venture with DemeRx to Develop Ibogaine For Opioid Use Disorder
January 24, 2020
Articles
9:30 am
JOIN THE ATAI #INSIGHTNETWORK
Receive the latest news on atai and innovations in the space.
Email